Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    83
    ...
ATC Name B/G Ingredients Dosage Form Price
L01EF01 PALBOMED G Palbociclib - 100mg 100mg Capsule 23,911,751 L.L
M01AE01 DOLORAZ 400 G Ibuprofen - 400mg 400mg Capsule 295,645 L.L
N03AX16 PREGAFORTE 75 G Pregabalin - 75mg 75mg Capsule 793,507 L.L
N06AB05 DEPROX G Paroxetine (HCl) - 40mg 40mg Tablet 2,909,099 L.L
R01AD11 RINEX G Triamcinolone acetonide - 55mcg/actuation 55mcg/actuation Spray, suspension 712,876 L.L
R06AX13 APOTHECARE LORATADINE G Loratadine - 10mg 10mg Tablet 495,878 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 0.5mg 0.5mg Tablet, coated L.L
A02BC01 OMEPRAZOLE PHARMADEX G Omeprazole - 20mg 20mg Capsule 15,757,784 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 191,913 L.L
C03CA01 DIURESAL G Furosemide - 40mg 40mg Tablet, scored 118,258 L.L
C10AA05 TORVALIP 20 G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 972,686 L.L
D07CC01 TOPIZONE G Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 216,359 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 20mg 20mg Tablet 1,111,358 L.L
J01CR02 JULMENTIN 2X G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet 401,809 L.L
J01MA02 CIPROLON 500 G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 295,645 L.L
L01EF01 PALBRANCE 100 G Palbociclib - 100mg 100mg Capsule 168,011,222 L.L
M01AE01 IBUPROFEN B. BRAUN G Ibuprofen - 400mg/100ml 400mg/100ml Injectable solution 231,141 L.L
N02AF02 NALBUPHINE RENAUDIN 1% G Nalbuphine HCl - 20mg/2ml 20mg/2ml Injectable solution 1,181,238 L.L
N03AX16 PREGASTAR G Pregabalin - 75mg 75mg Capsule, hard 628,482 L.L
R06AX13 CLARA G Loratadine (micronised) - 10mg 10mg Tablet 131,697 L.L
L01EB01 GEFITINIB ARROW G Gefitinib - 250mg 250mg Tablet, coated L.L
A02BC01 OMEZOL BENTA G Omeprazole - 20mg 20mg Capsule 550,336 L.L
A07EA06 ENTOCORT CIR G Budesonide - 3mg 3mg Capsule, hard, modified release 7,823,588 L.L
A10BK01 DIVINUS G Dapagliflozin propanediol - 5mg 5mg Tablet, film coated 2,145,848 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 208,002 L.L
C03CA01 FURESIX 40 G Furosemide - 40mg 40mg Tablet 166,381 L.L
C09CA03 ANGINET G Valsartan - 80mg 80mg Tablet, film coated 387,027 L.L
C10AA05 TOVAST G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,127,484 L.L
D07CC01 ZETA-CORT G Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 244,579 L.L
G04BE08 DURALIS G Tadalafil - 20mg 20mg Tablet, film coated 1,204,979 L.L
    ...
    83
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025